Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Shares Outstanding 2011-2025 | IRWD

Ironwood Pharmaceuticals shares outstanding from 2011 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Ironwood Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2024 160
2023 155
2022 186
2021 164
2020 161
2019 156
2018 153
2017 149
2016 145
2015 142
2014 137
2013 116
2012 106
2011 100
2010 90
Ironwood Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2025-06-30 177
2025-03-31 161
2024-12-31 160
2024-09-30 160
2024-06-30 159
2024-03-31 158
2023-12-31 155
2023-09-30 187
2023-06-30 155
2023-03-31 187
2022-12-31 186
2022-09-30 184
2022-06-30 185
2022-03-31 190
2021-12-31 164
2021-09-30 165
2021-06-30 163
2021-03-31 162
2020-12-31 161
2020-09-30 160
2020-06-30 160
2020-03-31 160
2019-12-31 156
2019-09-30 157
2019-06-30 156
2019-03-31 155
2018-12-31 153
2018-09-30 153
2018-06-30 152
2018-03-31 151
2017-12-31 149
2017-09-30 150
2017-06-30 149
2017-03-31 148
2016-12-31 145
2016-09-30 145
2016-06-30 145
2016-03-31 144
2015-12-31 142
2015-09-30 142
2015-06-30 142
2015-03-31 141
2014-12-31 137
2014-09-30 139
2014-06-30 138
2014-03-31 130
2013-12-31 116
2013-09-30 121
2013-06-30 113
2013-03-31 108
2012-12-31 106
2012-09-30 114
2012-06-30 107
2012-03-31 104
2011-12-31 100
2011-09-30 100
2011-06-30 100
2011-03-31 99
2010-12-31 90
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.335B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $75.529B 28.69
Zoetis (ZTS) United States $53.099B 19.00
Takeda Pharmaceutical (TAK) Japan $43.243B 8.82
Daiichi Sankyo, - (DSNKY) Japan $42.092B 20.96
BeOne Medicines - (ONC) Switzerland $35.245B 0.00
Sandoz Group AG (SDZNY) Switzerland $29.520B 0.00
United Therapeutics (UTHR) United States $19.266B 16.95
Merck (MKKGY) Germany $16.414B 10.67
Neurocrine Biosciences (NBIX) United States $15.330B 36.78
Shionogi (SGIOY) Japan $14.275B 13.11
Summit Therapeutics (SMMT) United States $13.935B 0.00
Ionis Pharmaceuticals (IONS) United States $12.096B 0.00
IPSEN (IPSEY) France $12.095B 0.00
Madrigal Pharmaceuticals (MDGL) United States $10.808B 0.00
Orion OYJ (ORINY) Finland $9.208B 26.31
Eisai (ESAIY) $8.260B 0.00
Corcept Therapeutics (CORT) United States $8.063B 87.10
Stevanato Group S.p.A (STVN) Italy $7.571B 44.64
Grifols, S.A (GRFS) Spain $5.934B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.730B 17.43
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.142B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $4.294B 0.00
Crinetics Pharmaceuticals (CRNX) United States $4.005B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $3.672B 17.45
Centessa Pharmaceuticals (CNTA) United Kingdom $3.016B 0.00
Dyne Therapeutics (DYN) United States $2.973B 0.00
Hypermarcas (HYPMY) Brazil $2.936B 22.07
Catalyst Pharmaceuticals (CPRX) United States $2.617B 8.38
Soleno Therapeutics (SLNO) United States $2.517B 0.00
Ocular Therapeutix (OCUL) United States $2.303B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.905B 22.58
Avadel Pharmaceuticals (AVDL) Ireland $1.841B 0.00
Guardian Pharmacy Services (GRDN) United States $1.836B 0.00
Xeris Biopharma Holdings (XERS) United States $1.594B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.510B 89.62
Ardelyx (ARDX) United States $1.446B 0.00
Harrow (HROW) United States $1.311B 0.00
Evotec AG (EVO) Germany $1.188B 0.00
Amylyx Pharmaceuticals (AMLX) United States $1.181B 0.00
Oruka Therapeutics (ORKA) United States $1.134B 0.00
Collegium Pharmaceutical (COLL) United States $1.129B 6.17
Relay Therapeutics (RLAY) United States $1.129B 0.00
Enliven Therapeutics (ELVN) United States $1.096B 0.00
Nektar Therapeutics (NKTR) United States $1.032B 0.00
Xencor (XNCR) United States $1.025B 0.00
Cronos Group (CRON) Canada $0.938B 0.00
ARS Pharmaceuticals (SPRY) United States $0.894B 0.00
ProKidney (PROK) United States $0.795B 0.00
Theravance Biopharma (TBPH) United States $0.753B 62.29
Savara (SVRA) United States $0.697B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.687B 6.13
Elite Pharmaceuticals (ELTP) United States $0.660B 0.00
Bioventus (BVS) United States $0.610B 12.51
Siga Technologies (SIGA) United States $0.604B 7.46
Aquestive Therapeutics (AQST) United States $0.598B 0.00
Esperion Therapeutics (ESPR) United States $0.593B 0.00
Zevra Therapeutics (ZVRA) United States $0.565B 0.00
Akebia Therapeutics (AKBA) United States $0.562B 0.00
KalVista Pharmaceuticals (KALV) United States $0.555B 0.00
Organogenesis (ORGO) United States $0.504B 0.00
4D Molecular Therapeutics (FDMT) United States $0.491B 0.00
Lexeo Therapeutics (LXEO) United States $0.443B 0.00
USANA Health Sciences (USNA) United States $0.373B 10.41
Galectin Therapeutics (GALT) United States $0.363B 0.00
Altimmune (ALT) United States $0.331B 0.00
Lyell Immunopharma (LYEL) United States $0.318B 0.00
Korro Bio (KRRO) United States $0.304B 0.00
Aldeyra Therapeutics (ALDX) United States $0.295B 0.00
Larimar Therapeutics (LRMR) United States $0.267B 0.00
Achieve Life Sciences (ACHV) Canada $0.252B 0.00
Nature's Sunshine Products (NATR) United States $0.249B 16.24
Aclaris Therapeutics (ACRS) United States $0.245B 0.00
Pyxis Oncology (PYXS) United States $0.243B 0.00
Journey Medical (DERM) United States $0.233B 0.00
AleAnna (ANNA) United States $0.217B 0.00
Avalo Therapeutics (AVTX) United States $0.216B 0.00
OmniAb (OABI) United States $0.205B 0.00
Heron Therapeutics (HRTX) United States $0.204B 0.00
MediWound (MDWD) Israel $0.201B 0.00
China SXT Pharmaceuticals (SXTC) China $0.193B 0.00
Profound Medical (PROF) Canada $0.177B 0.00
Protara Therapeutics (TARA) United States $0.171B 0.00
Innate Pharma SA (IPHYF) France $0.168B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.159B 0.00
Cassava Sciences (SAVA) United States $0.147B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.134B 0.00
Incannex Healthcare (IXHL) Australia $0.131B 0.00
Inhibikase Therapeutics (IKT) United States $0.127B 0.00
Cardiol Therapeutics (CRDL) Canada $0.108B 0.00
Surrozen (SRZN) United States $0.106B 0.00
Context Therapeutics (CNTX) United States $0.101B 0.00
Champions Oncology (CSBR) United States $0.094B 34.00
Avita Medical (RCEL) United States $0.093B 0.00
Vivani Medical (VANI) United States $0.093B 0.00
Metagenomi (MGX) United States $0.085B 0.00
Relmada Therapeutics (RLMD) United States $0.083B 0.00
Unicycive Therapeutics (UNCY) United States $0.081B 0.00
Prelude Therapeutics (PRLD) United States $0.079B 0.00
Dominari Holdings (DOMH) United States $0.078B 0.00
VAXART, INC (VXRT) United States $0.076B 0.00
Assertio Holdings (ASRT) United States $0.072B 0.00
Nutriband (NTRB) United States $0.072B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.071B 0.00
PMV Pharmaceuticals (PMVP) United States $0.069B 0.00
BioNxt Solutions (BNXTF) Canada $0.069B 0.00
Gain Therapeutics (GANX) United States $0.066B 0.00
Lite Strategy (LITS) United States $0.066B 0.00
Acrivon Therapeutics (ACRV) United States $0.064B 0.00
PolyPid (PYPD) Israel $0.060B 0.00
Talphera (TLPH) United States $0.059B 0.00
Wellgistics Health (WGRX) United States $0.059B 0.00
Fractyl Health (GUTS) United States $0.057B 0.00
Plus Therapeutics (PSTV) United States $0.054B 0.00
NRx Pharmaceuticals (NRXP) United States $0.053B 0.00
Century Therapeutics (IPSC) United States $0.048B 0.00
Jupiter Neurosciences (JUNS) United States $0.047B 0.00
Rafael Holdings (RFL) United States $0.047B 0.00
Karyopharm Therapeutics (KPTI) United States $0.046B 0.00
Telomir Pharmaceuticals (TELO) United States $0.045B 0.00
FibroGen (FGEN) United States $0.044B 0.00
Tempest Therapeutics (TPST) United States $0.044B 0.00
Inotiv (NOTV) United States $0.041B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.040B 0.00
ElectroCore (ECOR) United States $0.038B 0.00
Mural Oncology (MURA) Ireland $0.036B 0.00
Liminatus Pharma (LIMN) United States $0.035B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.035B 29.12
Klotho Neurosciences (KLTO) United States $0.033B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.033B 0.00
Iterum Therapeutics (ITRM) Ireland $0.030B 0.00
Scienture Holdings (SCNX) United States $0.027B 0.00
SCYNEXIS (SCYX) United States $0.026B 0.00
Enlivex Therapeutics (ENLV) Israel $0.024B 0.00
Citius Pharmaceuticals (CTXR) United States $0.023B 0.00
Cosmos Health (COSM) United States $0.022B 0.00
Vyome Holdings (HIND) United States $0.022B 0.00
Mangoceuticals (MGRX) United States $0.019B 0.00
Natural Alternatives (NAII) United States $0.018B 0.00
Vivos Therapeutics (VVOS) United States $0.018B 0.00
Mannatech (MTEX) United States $0.017B 0.00
Heatwurx (PCSA) United States $0.017B 0.00
CASI Pharmaceuticals (CASI) China $0.017B 0.00
Ainos (AIMD) United States $0.016B 0.00
Traws Pharma (TRAW) United States $0.015B 0.02
BioLineRx (BLRX) Israel $0.015B 0.00
Lipocine (LPCN) United States $0.014B 0.00
TherapeuticsMD (TXMD) United States $0.014B 0.00
Ernexa Therapeutics (ERNA) United States $0.013B 0.00
ProPhase Labs (PRPH) United States $0.012B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.012B 0.00
BioVie (BIVI) United States $0.012B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Lyra Therapeutics (LYRA) United States $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.009B 0.00
VYNE Therapeutics (VYNE) United States $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Aptorum Group (APM) United Kingdom $0.007B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Nuvilex (PMCB) United States $0.006B 0.00
Alaunos Therapeutics (TCRT) United States $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.006B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Qualigen Therapeutics (QLGN) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
CDT Equity (CDT) United States $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Indaptus Therapeutics (INDP) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
NewcelX (NCEL) Switzerland $0.002B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.000B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Indivior (INDV) United States $0.000B 16.35
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Minerva Neurosciences (NERV) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00